Recent Developments in Cellular Immunotherapy for HSCT-Associated Complications by Monica Reis et al.
November 2016 | Volume 7 | Article 5001
Review
published: 14 November 2016
doi: 10.3389/fimmu.2016.00500
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Martin Johannes Hoogduijn, 
Erasmus University 
Rotterdam, Netherlands
Reviewed by: 
Philippe Saas, 
Etablissement Français 
du Sang BFC, France  
Guido Moll, 
Charité, Germany
*Correspondence:
Anne Richter  
anner@miltenyibiotec.de
†Monica Reis, Justyna Ogonek, 
and Marsela Qesari contributed 
equally to this work.
Specialty section: 
This article was submitted to 
Alloimmunity and Transplantation, 
a section of the journal 
Frontiers in Immunology
Received: 11 July 2016
Accepted: 26 October 2016
Published: 14 November 2016
Citation: 
Reis M, Ogonek J, Qesari M, 
Borges NM, Nicholson L, Preußner L, 
Dickinson AM, Wang X-n, 
Weissinger EM and Richter A (2016) 
Recent Developments in 
Cellular Immunotherapy for 
HSCT-Associated Complications. 
Front. Immunol. 7:500. 
doi: 10.3389/fimmu.2016.00500
Recent Developments in 
Cellular immunotherapy for  
HSCT-Associated Complications
Monica Reis1†, Justyna Ogonek2†, Marsela Qesari3†, Nuno M. Borges1, Lindsay Nicholson1, 
Liane Preußner4, Anne Mary Dickinson1,3, Xiao-nong Wang1, Eva M. Weissinger2  
and Anne Richter4*
1 Haematological Sciences, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK, 2 Transplantation 
Biology, Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, 
Hannover, Germany, 3 Alcyomics Ltd., Newcastle upon Tyne, UK, 4 Miltenyi Biotec GmbH, Bergisch Gladbach, Germany
Allogeneic hematopoietic stem cell transplantation is associated with serious compli-
cations, and improvement of the overall clinical outcome of patients with hematological 
malignancies is necessary. During the last decades, posttransplant donor-derived 
adoptive cellular immunotherapeutic strategies have been progressively developed for 
the treatment of graft-versus-host disease (GvHD), infectious complications, and tumor 
relapses. To date, the common challenge of all these cell-based approaches is their 
implementation for clinical application. Establishing an appropriate manufacturing pro-
cess, to guarantee safe and effective therapeutics with simultaneous consideration of 
economic requirements is one of the most critical hurdles. In this review, we will discuss 
the recent scientific findings, clinical experiences, and technological advances for cell 
processing toward the application of mesenchymal stromal cells as a therapy for treat-
ment of severe GvHD, virus-specific T cells for targeting life-threating infections, and of 
chimeric antigen receptors-engineered T cells to treat relapsed leukemia.
Keywords: mesenchymal stromal cells, immunomodulation, extracellular vesicles, infection, adoptive transfer, 
chimeric antigen receptor, T cells, cell manufacture
iNTRODUCTiON
The medical need for improved therapeutic options to successfully treat patients with hematologic 
malignancies is high. Allogeneic hematopoietic stem cell transplantation (HSCT) is the only 
curative treatment for patients with hematologic malignancies, but the success of the therapy 
is limited by several severe side effects. One major obstacle with the highest transplant-related 
mortality rate is the recurrence of the underlying disease, due to failure in effective eradication 
of malignant cells by the reconstituted allogeneic immune system, mediated largely by T cells. 
The leading cause of non-relapse mortality is graft-versus-host disease (GvHD), an inflammatory 
immune reaction against healthy tissue of the patient, induced by donor-derived T cells and 
triggered by major and minor histocompatibility antigen differences between HSCT recipient and 
donor. Due to immunosuppressive treatment of the patient for prophylaxis and posttransplant 
therapy of GvHD, the appearance of life-threatening opportunistic infections is responsible for a 
substantial rate of non-relapse mortality. Thus, one of the biggest challenges for an effective treat-
ment with allogeneic HSCT is maintaining the balance between tolerance of the host, elimination 
of the malignancy, and protection against infections.
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Engineering of the allograft itself is one possible strategy to 
reduce the risk for development of GvHD and concomitantly 
remain the favorable immune reaction toward the tumor and 
infectious pathogens. The incidence and severity of GvHD 
can be reduced by ex vivo T cell removal either achieved via 
CD34+ hematopoietic stem cell enrichment or active depletion 
of T  cells, but these approaches have been associated with the 
risk for occurrence of graft rejection, relapse, and infections 
due to the missing T cells. However, for matched sibling donor 
transplantation in acute myeloid leukemia, it has been shown 
recently that ex vivo T cell depletion can reduce the incidence 
of chronic GvHD significantly without affecting the relapse rate 
(1, 2). The most novel procedures in graft manipulation aim for 
the elimination of potential alloreactive T cells only, allowing 
antiviral and antitumor T cells to remain in the transplant 
supporting tumor elimination and providing protection against 
infections (3–8).
Another strategy to control allogeneic HSCT-related 
complications is the adaptive transfer of ex vivo selected 
donor-derived immune cell populations after transplantation. 
At first, donor lymphocyte infusions (DLI) were established 
to prevent and treat relapses, but, subsequently, controlling 
infections became an important matter for concern (9, 10). 
DLI contain allogeneic T cells and are therefore associated 
with an increased risk for the onset of GvHD. These observa-
tions initiated the development of several adoptive therapies 
with selected immune cell populations depleted of alloreactive 
cells. Strategies that are followed include the adoptive therapy 
of regulatory T cells (Tregs) and mesenchymal stromal cells 
(MSCs) for treatment of GvHD, dendritic cell (DC) vaccina-
tion and natural killer (NK) cell transfer to support antitumor 
responses, as well as application of T cells to control infections 
or to induce antitumor responses (11–13).
Despite the differences in cell type and the underlying 
medical problem, which require specific considerations dur-
ing the translational phase, various hurdles are common for 
all cellular immunotherapies. At present, a variety of clinical 
protocols, including cell manufacturing processes, have been 
generated for each of the three therapeutic approaches and 
reached a stage of evaluation within clinical trials. However, 
the obstacles, prior to clinical application which remain, 
include the establishment of standardized clinical protocols 
and understanding the therapeutic mechanisms. Nevertheless, 
the promising and beneficial clinical outcomes of early-phase 
clinical studies, the enormous achievements in scientific 
understanding of immune interventions, and the innovative 
technical advances in cell manipulation and processing has 
led to a huge growth in interest in cellular immunotherapy, 
especially in the area of hematological diseases. To offer these 
new therapeutic options as standard-of-care treatments for all 
patients, various aspects have to be considered for the imple-
mentation into clinical practice, in particular with regard to the 
cell manufacturing. Cell-processing protocols, often developed 
in research laboratories using tools and technologies available 
or suitable for research application only, need to be process 
engineered to good manufacturing practice (GMP) prior to 
clinical application.
This review will discuss the challenges and recent progresses 
made toward clinical application of MSCs for the management of 
GvHD, antiviral T cells for the treatment of opportunistic viral 
infections, and chimeric antigen receptors (CAR)-engineered 
T  cells as an adoptive therapy for leukemia relapses. These 
three examples allow us to not only to highlight technological 
and clinical advances of the individual therapy but also discuss 
general aspects of translation, especially with regard to cell 
processing.
CLiNiCAL APPLiCATiON wiTH 
MeSeNCHYMAL STROMAL CeLLS FOR 
THe MANAGeMeNT OF GvHD
Mesenchymal stromal cells are multipotent progenitor cells, 
which can be acquired from various adult tissues, primarily 
bone marrow (BM) (14). Their immunomodulatory property has 
empowered them to play an important role as a cellular therapy for 
GvHD (15). GvHD is a frequent and potentially life-threatening 
complication after allogeneic HSCT, affecting 40–60% of patients, 
and a leading cause of non-relapse mortality (16, 17). Despite 
significant advances in the understanding of GvHD pathogenesis 
and the development of transplantation medicine, corticosteroids 
remain the first-line treatment of GvHD, but with only an approx-
imately 50% response rate. Patients who fail the standard steroid 
treatment have an overall survival rate of only 5–30% (18–20). 
Apart from the low response rate, steroid treatment also bears the 
risk of increased leukemia relapse and opportunistic infections. 
To improve the efficacy of GvHD management, several cellular 
immunotherapies have been developed using MSCs as well as 
DCs and Tregs (17, 21, 22).
Lessons Learned from Recent 
Clinical Trials
Since the first case report in which infusion of haploidentical 
MSCs showed a beneficial outcome in the treatment of severe 
treatment-refractory acute GvHD (aGvHD) (23), an increasing 
number of clinical trials have been conducted to evaluate the 
effect of MSC infusion on GvHD for over a decade (17, 24, 25). 
The outcome of early clinical trials has been well reviewed. This 
article mainly collates recent clinical studies, reported between 
2010 and 2015, on the prophylactic and therapeutic use of MSCs 
for aGvHD. The relevant information is summarized in Table 1 
(26–29) and Table 2 (15, 30–38), respectively.
These reports have shown encouraging results indicative of 
positive steps taken toward the development of a more refined 
MSC therapy, although significant improvements are still 
needed. First, recent clinical studies have shown a clear trend 
toward replacing fetal calf serum (FCS) with human platelet 
lysate (hPL) to generate MSCs. Until the first clinical trial uti-
lizing hPL-expanded MSCs to treat aGvHD being reported in 
2009 (25), all clinical trials in the HSCT setting were performed 
using MSCs expanded in FCS-containing medium, a condition 
no longer accepted under current regulatory GMP require-
ments. As illustrated in Table  2, 40% (4/10) of clinical studies 
published between 2010 and 2015 have used MSCs expanded 
TABLe 2 | Therapeutic use of MSC infusion for steroid-resistant/refractory aGvHD.
MSCs HSCs No. Pts Clinical outcome Reference
BM, third party BM, PBSC, CUB 28 CR: 61% (15)
1 × 106/kg HLA identical OR: 75%
2–8 infusions Haploidentical
HLA-mismatched
BM-PL, third party BM, PBSC, UCB 40 CR: 27.5% (30)
1.5 × 106/kg HLA identical OR: 67.5%
1–5 infusions Haploidentical
HLA-mismatched
BM-PL, third party NR 25 CR: 46% (31)
1.1 × 106/kg OR: 71%
2–4 infusions
BM, third party BM, PBSC, UCB, DLI 75 CR: NR (35)
2 × 106/kg HLA-matched OR: 61.3%
8–12 infusions HLA-mismatched
BM, third party n = 34 BM, PBSC, UCB, DLI 37 CR: 65% (36)
1–2 × 106/kg HLA identical, MUD OR: 86%
1–13 infusions Haploidentical
BM, third party BM, PBSC, UCB 50 CR: 34% (37)
1.1 × 106/kg HLA identical, MUD IR: 66%
1–4 infusions Haploidentical, UCB
BM, third party PBSC 12 CR: 58.3% (38)
1.7–2.3 × 106/kg MUD OR: 91.7%
2–8 infusion
BM-AS/AS + PL BM, PBSC 10 CR: 10% (32)
haplo- & RD HLA-matched OR: 70%
1–2 × 106/kg HLA-mismatched
1–4 infusions
BM, third party BM, PBSC, UCB 12 CR: 58% (34)
8 × 106/kg n = 2 HLA-matched OR: 75%
2 × 106/kg n = 10 HLA-mismatched
8–12 infusions
BM-PL, third party BM, PBSC, UCB 11 CR: 23.8% (33)
1.2 × 106/kg HLA-matched OR: 71.4%
1–5 infusions HLA-mismatched
No. Pts, number of patients; BM, bone marrow; PBSC, peripheral blood stem cells; UCB, umbilical cord blood; DLI, donor lymphocyte infusions; MUD, HLA-matched unrelated 
donor; RD, related donors; HSC, hematopoietic stem cells; NR, not reported; BM-PL, platelet lysate expanded MSC; BM-AS, human serum expanded MSC; CR, complete 
response; OR, overall response; IR, initial response.
TABLe 1 | Prophylactic use of MSCs to prevent GvHD.
MSCs HSCs MSC group Ctrl group Observation on GvHD incidence/severity Reference
UCB BM, PBSC 21 None 9 of 21 patients developed aGvHD (II–IV) (27)
0.5 × 106/kg Haploidentical
Single dose Without TCD
UCB BM, PBSC 50 None 12 of 50 patients developed aGvHD (II–IV) (26)
0.5 × 106/kg Haploidentical
Single dose
BM-PL of HSC donor BM 19 18 1 of 19 patients had aGvHD in MSC group (28)
0.9–1.3 × 106/kg Donor type NR Randomized 6 of 18 patients had aGvHD (II–IV) in Ctrl group
Single dose
BM, third party PBSC 20 16 9 of 20 patients had aGvHD (II–IV) in MSC group (29)
0.9–1.3 × 106/kg MMR or MMU Historic 9 of 16 patients had aGvHD (II–IV) in Ctrl group
Single dose
BM, bone marrow; PBSC, peripheral blood stem cells; UCB, umbilical cord blood; HSCs, hematopoietic stem cells; NR, not reported; BM-PL, platelet lysate expanded MSC; MMR, 
HLA-mismatch related donors; MMU, HLA-mismatched unrelated donors; TCD, T cell depletion.
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in hPL or human serum (30–33), which provides evidence and 
confidence for a xeno-free era of MSC production. Second, in 
90% (9/10) of recent clinical trials, MSCs have been generated 
from third-party donors (Table 2), and some patients received 
different batches of MSCs derived from two or more donors (15, 
34, 35). This has further strengthened the concept response rates 
4Reis et al. Translation of Cellular Immunotherapy
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are independent on HLA-matching and reinforced the feasibility 
of using pre-manufactured “off-the-shelf ” MSCs as a therapeutic 
agent (34, 35). On the other hand, recent clinical studies have 
also exposed significant limitations in the field. Although the 
reported response rates indicate some effect of MSCs on GvHD, 
their therapeutic efficacy remains ambiguous with complete and 
overall response rates varying from 10 to 65% and 61 to 91%, 
respectively, across the studies (Table 2). This can be attributed to 
multifactorial factors such as small patient cohort, lack of uniform 
efficacy measure and appropriate control groups in the analysis, 
heterogeneity in patient/MSC populations, and varying HSCT 
regimens. The lack of standardized protocols for MSC produc-
tion and differences in dose/timing of MSC delivery could also 
contribute to the inconsistent results. These limitations highlight 
the need to interpret reported therapeutic efficacy with caution 
and preclude a definitive conclusion for the efficacy of MSCs in 
the treatment of GvHD.
Collectively, although the therapeutic efficacy of MSCs 
remains controversial, clinical studies consistently suggest that 
MSCs are safe to infuse in humans with no acute toxicity and 
no ectopic tissue formation, irrespective of their origin, culture 
conditions, and doses (17, 34, 39, 40). No association has been 
observed between MSC therapy and organ complications, death, 
or malignancy (41). This safety record allows future trials to be 
conducted using improved trial design and optimized practical 
procedures. Due to their immunosuppressive nature, whether 
MSC infusion could increase the risk of leukemia relapse and/
or infectious diseases has been an area of concern. Results 
from clinical studies are highly controversial (40, 42, 43). This 
subject has been extensively discussed in a recent review (44). 
To date, MSC therapy in HSCT settings remains exploratory 
and experimental.
Manufacturing of GMP-Compliant 
MSC Products
Among a spectrum of challenges, GMP-compliant cell produc-
tion is one of the most critical steps. Translation of pre-clinical 
MSC amplification into clinical-grade large-scale expansion 
presents a big challenge for the development of a successful 
therapy. As with any cell therapy, the manufacturing process of 
MSCs for human use must follow GMP conditions and appropri-
ate regulations to ensure product efficacy and safety. To achieve 
this, specialized GMP facilities, equipments, and trained staff 
are required. In addition, the unique characteristics of MSCs 
regarding cell source and cell culturing, including cell seeding, 
expansion, and culture medium, have to be considered. MSCs 
are mainly generated from BM, but umbilical cord and adipose 
tissue are also considered as well as a reliable source. Due to 
the low frequency of MSCs in BM (0.001–0.01%), large-scale 
ex vivo expansion is a pre-requisite to achieve the required cell 
dose of about 1–2 ×  106/kg, in total around 100–200 million 
cells/patient prior to clinical application (45). A very important 
factor to allow for a good expansion of MSCs is the density of 
plating the cells. As MSC are adherent cells, their growth is 
inhibited by reaching confluence. As a consequence, successive 
passaging of the cells has to be performed, and, typically after 
3 weeks of culture, the proliferation rate and the differentiation 
potential declines. Furthermore, the increasing age of the donor 
is reported to be linked with a reduced expansion and multi-
potency (46). Details on standardization of the production of 
clinically applied products and further requirements have been 
summarized in several reviews (47, 48).
Development of Xeno-Free Expansion Medium
For the purpose of human applications, The International 
Society of Cellular Therapy (ISCT) recommends that reagents 
used for cell processing be free of xenogeneic products, due 
to the potential for infections, and that expansion be limited 
to early passages, due to the theoretical risk of cell senescence 
and malignant transformation. Conventionally, FCS is used for 
MSCs expansion for research applications and most clinical 
trials so far. FCS is a complex mixture of mitogenic factors 
which contribute to the maintenance and proliferation of 
MSCs in  vitro (49). It is by nature ill-defined and exhibits 
batch-to-batch variability (50). It could be associated with the 
transmission of prions and undefined zoonosis as well as an 
increased risk of triggering adverse immune reactions resulting 
in the elimination of infused MSC, especially when multiple 
infusions are required (51). Therefore, the use of FCS is being 
criticized and strongly discouraged by the regulatory agencies, 
which urge for the development of GMP-compliant media, 
either serum- or animal-free, that can be standardized and 
used in both, research and clinical trials.
Over the last decade, numerous laboratories have been 
focused on the development of medium formulations that are 
either serum-free or use human blood-derived products, such as 
human autologous or pooled allogeneic serum, cord blood, and 
platelet derivatives (49, 51–55). Despite promising results with 
these culture supplements, the use of platelet derivatives, more 
specifically hPL has illustrated the best results. hPLs are manu-
factured by platelet disruption, using freeze/thaw protocols. 
Relatively standardized batches of hPL are produced by pooling 
platelet concentrates of several healthy donors (56). Repeated 
freezing/thawing of platelet concentrates allows the release of 
growth factors at a higher level that those in most FCS batches, 
such as basic fibroblast growth factor (bFGF), insulin growth 
factor 1 (IGF1), platelet-derived growth factor (PDGF), and 
transforming growth factor beta (TGF-β) (57). Several studies 
have demonstrated the use of hPL for MSC expansion provides 
increased proliferative capacity, while maintaining differentia-
tion and immunomodulatory properties (57–59). These promis-
ing results have prompted the use of hPL-generated MSCs in 
clinical applications. Currently, 11 registered clinical studies 
are ongoing utilizing hPL-expanded MSCs for the treatment 
of GvHD, Crohn’s disease, and diabetes (www.clinicaltrials.
gov; as for 10/2016). Meanwhile, GMP-grade complete media 
specially developed for MSC expansion are commercially 
available, which also achieve higher expansion rate and thereby 
shorten the production time and the associated risk of product 
contamination (48).
Culture Systems and Product Release
Classically, MSC expansion is performed in open culture systems 
using numerous plastic culture flasks or cell stacks. Manual 
TABLe 3 | Nomenclature and classification of the different types of vesicles.
Characteristics exosomes Microvesicles Apoptotic bodies
Size 20–100 nm 50–1000 nm 500–5000 nm
Shape Cup shaped Irregular Heterogeneous
Sedimentation 100,000 × g Size dependent at 100,000 × g, 10,000 × g, and 
2000 × g
Size dependent at 100,000 × g, 
10,000 × g, and 2000 × g
Sucrose gradient 1.13–1.19 g/ml 1.04–1.07 g/ml 1.16 and 1.28 g/ml
Markers Tetraspanins (CD63/CD9), Alix, TSG1, ESCRT 
components, flotilin
Integrins, tetraspanins, selectins, and CD40 ligand Histones
Lipids Cholesterol, sphingomyelin, ceramide, lipid rafts, 
phosphatidylserine
Phosphatidylserine High amounts of 
phosphatidylserine
Origin Endolysosomal pathway; intraluminal budding into 
multivesicular bodies and released by fusion of the 
multivesicular bodies with the cell membrane
Cell surface; outward budding of cell membrane Cell surface; outward blebbing 
of apoptotic cell membrane
Contents mRNA, microRNA, and other non-coding 
RNAs; cytoplasmic and membrane proteins 
(including HSP and cell-specific receptors)
mRNA, microRNA (miRNA), and other non-coding 
RNAs; cytoplasmic proteins and membrane proteins, 
including cell-specific receptors
Nuclear fractions and cell 
organelles
ESCRT, endosomal sorting complexes required for transport; MVB, multivesicular bodies; HSP, heat-shock protein; mRNA, messenger RNA.
Table has been adapted from published literatures (90, 259, 260).
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handling steps for sequential cell passaging are labor intensive 
and time consuming, as well as bearing the risk for contamination. 
In this respect, automated and closed devices would simplify the 
manufacturing and increase product safety. Suitable bioreactors 
for MSC expansion on the market are the Quantum® (Terumo) 
and Scinus Cell Expansion™ (Xpand Biotechnology). In addition, 
the CliniMACS Prodigy® (Miltenyi Biotec) allows automated cell 
processing starting from sample preparation to cell culture and 
magnetic cell separation until the final formulation of the cellular 
product in a closed system by using single-use tubing sets (60). 
The instrument has the capability for preparation of mononuclear 
cells from BM samples using high-density gradient centrifugation 
prior to cell expansion. Additionally, magnetic enrichment steps 
for MSCs could be integrated into the manufacturing process, 
either before or after the expansion phase to further increase the 
purity of the cellular product.
Regarding the quality control for product release, the ISCT 
recommendation is to test for three characteristics of MSCs: (1) 
adherence to plastic; (2) expression of defined MSC cell surface 
markers, including positivity for CD73, CD90, and CD105 but 
negative for hematopoietic cell markers CD14, CD19, CD34, 
CD45; and (3) differentiation ability toward osteoblastic, 
chondrogenic, and adipocytic linages (61). Further tests, such 
as immunopotency assays and cytogenetic analysis remain at 
the discretion of the regulatory authorities (62). Ultimately, the 
most pressing issue relating to therapeutic efficacy is the fact 
that currently no standardized immune potency assay exists 
for quality control. This is partly complicated by their complex 
mechanism of action and the lack of understanding regarding 
MSC distribution and overall fate after infusion. However, 
a recent publication has described three tests defined in an 
ISCT workshop as potential release criteria: quantitative RNA 
analysis of selected gene products related to the cell’s immu-
nomodulatory function, flow cytometry analysis of functionally 
relevant surface markers, and a protein-based assay of the MSC 
secretome (63). Together, these could provide appropriate 
guidance for releasing products, however not enough evidence 
currently exists to support their definitive use. Furthermore, 
a comprehensive understanding in the mechanisms of action 
of MSCs holds the key to successful development of future 
MSC therapies.
MSC-Derived extracellular vesicles
Extracellular vesicles (EVs) are nanovesicles secreted by various 
cell types and are composed of a phospholipid bilayer, including 
transmembrane proteins and cell-specific receptors, enclosing 
cytoplasmic components. EVs are responsible for the horizontal 
transfer of bioactive proteins and genetic material, by inter-
nalization into endocytic compartments, fusion with plasma 
membranes, and/or by recognition of specific receptors (64). 
EVs can be easily isolated from cell culture medium and have 
been detected in a wide variety of bodily fluids (65–75). There are 
three major types of EVs: exosomes, microvesicles, and apoptotic 
bodies (76). A general description of these types and their cor-
responding characteristics can be found in Table 3. The two main 
types of EVs are microvesicles and exosomes, of which the latter 
are the most abundant.
General Features of MSC-EVs
Mesenchymal stromal cells-extracellular vesicles are constitu-
tively secreted by MSCs and can be identified by transmission 
electron microscopy as cup-shaped nanovesicles with sizes 
ranging from 20–150 nm in diameter (Figure 1). They are rich 
in adhesion molecules, such as intercellular adhesion molecule 
1 (ICAM-1), lysosomal-associated membrane 2 (LAMP-2), 
tetraspanins (e.g., CD9, CD63, CD81), integrins (e.g., CD49C, 
CD49D), heat-shock proteins, cytoskeletal proteins, and mem-
brane trafficking proteins, such as “Ras-related in brain” (67) and 
annexins (77, 78). Moreover, they express cell-specific molecules, 
including CD29, CD73, CD44, and CD105, and enclose proteins 
involved in MSC self-renewal and differentiation (GF, Wnt, TGF-
β, MAPK, BMP, etc) (77). MSC-EVs also carry a variety of genetic 
FiGURe 1 | Transmission electron microscopy micrograph of 
whole-mounted extracellular vesicles-purified human MSCs. 
MSC-EVs exhibit a spheroid, cup-shaped morphology. Scale bar shows 
100 nm. Photography courtesy of Monica Reis.
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material, including mRNA and non-coding RNA [pre-micro-
RNA (miRNA), miRNA, tRNA, piRNA] (79–81). Significant 
importance has been given to MSC-EV shuttled miRNA, which 
has been shown to be functionally active and involved in the 
regulation of genes related to organ development, cell survival, 
and differentiation (82–85). The lipid composition of MSC-EV 
is still unknown; however, very recently, Lai and colleagues have 
reported an enrichment of phosphatidylserine (86). This lipid has 
been identified on the surface of various types of EVs, derived 
from various types of cells, and has been described as an evo-
lutionary conserved immunosuppressive signal which promotes 
tolerance and prevents the activation of the immune system (87). 
Recently, Wei et al. have demonstrated that phosphatidylserine 
on the surface of MSC-derived microvesicles is essential for their 
uptake by human umbilical vein endothelial cells (HUVECs), 
however, the role of this lipid in MSC-EV-derived immunosup-
pression is still unexplored (88).
Common Procedures for EV Purification
Currently, differential ultracentrifugation represents the gold 
standard and most commonly used protocol for EV purification. 
This protocol involves several centrifugation steps at different 
speeds to eliminate cell debris and protein contaminants (89). 
EV sedimentation is usually accomplished by ultracentrifuga-
tion of the pre-cleared biofluid at speeds of 100,000 ×  g. This 
protocol varies across users which may lead to inconsistences 
in EV yields. In some protocols, EV sedimentation is accom-
plished at higher-speed ultracentrifugation (e.g., 140,000 ×  g) 
and longer centrifugations (e.g., 4–7  h). Alternatively, the last 
ultracentrifugation step can be replaced by microfiltration or 
followed by an extra purification step, e.g., sucrose-gradient 
centrifugation, which yields a cleaner EV population without 
co-precipitation or protein contaminants (89). Other EV puri-
fication methodology includes the use of commercially available 
kits based on polymer-precipitation and immune-capture using 
antibody-coated magnetic beads (90). The commercially avail-
able kits precipitate a wide range of vesicles, however, it may 
display concomitant precipitation of protein contaminants, while 
the immunolabeled beads only precipitates a restricted fraction of 
EVs and neglects others (90). Laboratories worldwide have been 
focused on the refinement of protocols to allow for a more robust 
purification and yield a purer EV population.
Therapeutic Potential of MSC-Derived evs
Since the initial identification of EVs in the conditioning 
medium of MSCs, increasing studies have demonstrated that 
MSC-EVs harness therapeutic effects. MSC-derived EVs have 
been shown to recapitulate the therapeutic effect of the parent 
cells in animal models of cardiac, kidney, and brain injuries 
and the observation MSCs have restricted migration and sur-
vival potential argues for the clinical use of EVs (91–94). The 
importance of MSC-EVs has also been identified as one of the 
mechanisms of MSC immunomodulation. MSC-EVs have been 
reported to modulate proliferation and differentiation of T cells, 
B cells, and monocytes (Table  4). Budoni et  al. demonstrated 
that the effect of MSCs on B cell proliferation and differentia-
tion could be fully reproduced by MSC-EVs and that this was 
inhibited in the presence of MSC-EVs in a CpG-stimulated 
peripheral blood mononuclear cell coculture system, in a dose-
dependent manner (95). The effect of MSC-EVs on T cells was 
initially investigated by Mokarizadeh et al. in 2012. MSC-EVs 
were shown to express regulatory receptors, such as programed 
death ligand 1 (PD-L1), galectin-1, and membrane-bound 
TGF-β1, and were able to inhibit auto-reactive lymphocyte 
proliferation, promote the production of IL-10 and TGF-β, and 
increase apoptosis of recipient T cells (96). MSC-EVs seemed 
to induce tolerogenic signaling by prompting the generation 
of CD4+CD25+FoxP3+ Tregs (96). These findings were further 
corroborated by different independent studies which showed 
that MSC-EVs were capable of reducing proliferation and IFN-γ 
release of in vitro stimulated T cells in a dose-dependent manner 
and that one of the main mechanisms of MSC-EV to regulate 
T-cell proliferation and activation was the generation of de novo 
Tregs (97–99). Zhang et  al. demonstrated that this effect was 
indirect and that MSC-EVs were preferentially taken up by 
splenocytes, which in turn polarized activated CD4+ T cells to 
that of a CD4+CD25+FoxP3+ Treg phenotype. In this study, the 
authors proposed that MSC-EVs are responsible for the activa-
tion of TLR-dependent signaling in macrophages, which leads 
to the induction of an IL-12loIL-10hi M2 phenotype. These M2 
macrophages are then responsible for the generation of Tregs 
(100). Additionally, infusion of MSC-EVs led to enhanced 
survival of allogeneic skin grafts in mice (100). Recently, Favaro 
et al. demonstrated that MSC-EVs internalized by DCs impaired 
their in  vitro maturation, with reduced expression of matura-
tion markers CD86, CD80, and CD83, and an increase in IL-10 
production by the EV-conditioned DCs (101).
Mesenchymal stromal cells-extracellular vesicles have also 
been tested in the context of HSCT and GvHD. A recent study has 
provided initial evidence that MSC-EV treatment combined with 
HSCs contributes to faster reconstitution of the hematopoietic 
TABLe 4 | Summary of the immunomodulatory potential of MSC-evs.
Target cells experimental approach Source of evs and isolation 
method
Results Reference
PBMC In vitro coculture Human umbilical cord MSC  Proliferation of CD8+ and CD4+ (99)
UC (Sed.: 10,000 × g) and  
Exoquick
 Percentage of CD4+CD25+FoxP3+ Tregs
 TGF-β1 and IL-10;  IFN-γ, IL-6, TNF-α
Colon cells TNBS-induced colitis model Human BM-MSCs  Pro-inflammatory cytokine levels in injured colons (261)
UC (Sed.: 100,000 × g) Suppression of apoptosis
Inhibition of NF-kBp65 signal transduction pathways
T lymphocytes In vitro coculture Human ASCs Decreased T-cell activation and proliferation (97)
UC (Sed.: 100,000 × g)
Auto-reactive 
lymphocytes
EAE mice Murine BM-MSCs EVs express PD-L1, galectin-1, and TGF-β1 (96)
UC (Sed.: 100,000 × g) Inhibition auto-reactive T-cell responses
 Apoptosis
 CD4+CD25+FoxP3+ Tregs
PBMC from type I 
diabetes patients
In vitro coculture Human BM-MSC  IFN-γ production and  TGF-β, IL-10, IL-6, and PGE2 (98)
UC (Sed.: 100,000 × g)  Level of Th17 cells and  FoxP3+ Tregs
B lymphocytes In vitro coculture Human BM-MSC Inhibition of B-cell proliferation and differentiation (95)
UC (Sed.: 100,000 × g) and UF
THP-1 MФ In vitro coculture and in vivo 
injection of EVs in a mouse 
model of allogeneic skin  
grafting
Human ESC-MSC  Anti-inflammatory cytokines (100)
HPLC  Pro-inflammatory cytokines
TLR-dependent induction of M2-like phenotype
Treg cell expansion
In vitro coculture LPS treated UC-MSC MФ polarization via delivery of Let-7b by EVs and 
inhibition of TLR4 signaling pathway
(84)
UC (Sed.: 100,000 × g)
moDCs from type I 
diabetic patients
In vitro coculture Human BM-MSC EV-conditioned DCs exhibited immature phenotype (101)
UC (Sed.: 100,000 × g)  IL-10, IL-6, and TGFβ
 IL-17 and Th17 cells
Treg expansion
Sed., sedimentation rate; UC, ultracentrifugation; UF, ultrafiltration; Tregs, regulatory T cells; EAE, experimental autoimmune encephalomyelitis; TNBS, 2,4,6 trinitrobenzene sulfonic 
acid; HPLC, high performance liquid chromatography; BM-MSC, bone marrow-derived MSC; ASC, adipocyte-derived stem cells; NF-kBp65, nuclear Factor kappa B p65; TGF-β1, 
transforming growth factor beta 1; IL-10, interleukin 10; IFN-γ, interferon gamma; IL-6, interleukin 6; TNF-α, tumor necrosis factor alpha; PD-L1, programed death ligand 1; PGE2, 
prostaglandin E2; TLR, toll-like receptor; IL-17, interleukin 17; Th, T-helper cell; MФ, macrophage; moDCs, monocyte-derived dendritic cells; LPS, lipopolysaccharide; FoxP3, 
forkhead box P3.
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microenvironment. In this study, MSC-EVs were shown to be 
enriched in miRNAs that promote UCB-CD34+ migration and 
engraftment in the BM niche (83). Amarnath et  al. detected 
CD73-expressing EVs in MSC recipients in a mouse model of 
GvHD. These EVs were found to metabolize extracellular ATP 
into adenosine and, as a consequence, to inhibit Th1 cell effector 
function (102). In 2014, Kordelas et al. were the first to admin-
ister MSC-EVs in a steroid-refractory GvHD patient. MSC-EV 
preparations were shown to contain high concentrations of anti-
inflammatory molecules IL-10, TGF-β, and HLA-G and were 
administered to the patient at intervals of 2 or 3 days for a period 
of 2 weeks. MSC-EV administration was well tolerated and no 
side effects were reported. The patient exhibited a 50% decrease in 
the production of the pro-inflammatory cytokines IL-1β, TNF-α, 
and IFN-γ and concomitant a reduction of diarrhea and cutane-
ous and mucosal GvHD, which remained stable for more than 
4 months post MSC-EV treatment (103).
Future Perspectives of MSC Therapy
Donor Source and the Use of Freeze–Thawed 
MSC Products
A long standing debate is the donor source of MSCs, particularly 
autologous versus allogeneic, and single-donor versus pooled 
donor batches (also called “master cell stocks”). Largely, the pros 
and cons of each relate to development costs and product safety. 
Autologous MSCs are innately safe from an immunological/infec-
tive perspective and obviate the search for a third-party donor. 
However, allogeneic MSCs would allow for product preparation 
in advance for infusion as an “off the shelf ” treatment, without 
delays for the recipient. The advantages of master cell stocks 
are seemingly obvious, as they would allow mass production of 
MSCs for clinical use in multiple patients; as opposed to the need 
to isolate, expand, and quality check a batch of MSCs for every 
single recipient. However, not only would MSC production at an 
industrial scale prove costly, the potential for the contamination 
of multiple individuals with a single batch would require even 
more rigorous product analysis to ensure safety, which would 
only increase development costs further.
Another area of controversy is the clinical response and 
efficacy of using fresh (from culture) versus thawed MSCs. 
In  earlier clinical trials, MSCs were infused into patients as 
thawed products, due to the benefit of cryopreservation allowing 
for long-term storage and use at a later date. However, recently 
the clinical effectiveness and safety of these products have been 
questioned (104). In vitro, it has been shown that post-thaw MSCs 
display a weaker immunomodulatory profile compared to their 
pre-freeze counterparts due to a heat-shock response, particularly 
in relation to weak IDO secretion (105). This seems to correlate 
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with clinical outcomes, with reports of double the response rates 
in fresh compared to thawed MSCs for the treatment of HSCT 
complications (106). Despite aforementioned evidence, a recent 
study has examined the effect of cryopreservation on human 
MSC viability, immunomodulatory potency, and performance in 
an ischemia/reperfusion injury model. This study has observed 
that with modifications to standard cryopreservation methods 
over 95% MSC viability could be achieved upon thawing. These 
thawed high viability MSCs maintained their function in sup-
pressing human mononuclear cell activation. Furthermore, the 
study has demonstrated that when viability is maintained, MSCs 
retained their therapeutic potency in an in vivo ischemia/reperfu-
sion injury mode (107). This controversial evidence highlights 
potential risks as well as achievable hopes for an off-the-shelf 
therapy. Further studies are warranted to provide the field with a 
more definitive view.
From a safety perspective, concerns have also been raised 
regarding the possibility that post-thaw MSCs are associated with 
an increased rate of the so-called instant blood-mediated inflam-
matory reaction (IBMIR) (106). As seen with islets of Langerhans 
cells, this physiological process involves activation of a number of 
components, mainly the coagulation and complement cascades, 
leading to leukocyte and platelet activation, and subsequent tissue 
damage (108, 109). The extent of this, however, remains unclear, 
and more importantly, this has not been shown to have a negative 
impact on the safety profile of MSCs.
Mechanisms of Action of MSCs
Despite their potential therapeutic benefits in GVHD treatment, 
the exact mechanisms of action of MSCs are yet to be fully eluci-
dated. Increasing evidence has led to a common consensus that 
the efficacy of MSC therapy could be predominantly attributable 
to the release of soluble factors rather than long-term engraftment 
(110, 111). The MSC secretome includes an array of bioactive pro-
teins, such as cytokines, growth factors, and chemokines. Their 
functions and interactions, together with relevant literatures, 
have been summarized in Figure  2. Ultimately, establishing a 
comprehensive understanding of how MSCs work holds the key 
to the development of successful MSC therapies.
Considerations in Using MSC-EVs for Therapies
Current research suggests MSC-EV-based therapy could 
potentially have significant clinical relevance. In comparison 
with MSCs, MSC-EVs are non-self-replicating hence no risk of 
aneuploidy, less likely to be modified by inflammatory environ-
ment and have a lower possibility of immune rejection owing 
to their small size and lower expression of membrane-bound 
molecules, including membrane histocompatibility molecules. 
MSC-EVs are also more stable than the parent cells, by virtue of 
their encapsulated cargo, EVs provide added protection to their 
contents from in  vivo degradation, thus preventing problems 
associated with rapid breakdown of soluble molecules, such as 
cytokines, growth factors, and RNAs. In contrast to cell-based 
therapy, MSC-EV therapy can be easier to manufacture and safer, 
as they are devoid of cells and hence impose no danger of ectopic 
tissue formation. Additionally, they can be stored in non-toxic 
cryopreservatives at −20°C for 6 months with maintenance of 
biological activity (112). Despite these advantages, for clinical 
translation to be considered, it is essential to elucidate on the 
biological properties and the constituents of these vesicles, in 
terms of proteins and RNAs. MSC-EVs, as cellular products, 
are influenced by the secreting cells; therefore, it is inevitable 
that MSC heterogeneity will impact on EV cargo and biologi-
cal effects. Distinct MSCs have been shown to display different 
abilities to produce cytokines and to respond to inflammatory 
licensing (113). Moreover, donor age and gender also affect the 
functional characteristics of MSCs (114). Current studies have 
not clarified the effect of inter-individual variability of MSC-EVs, 
and only a few studies have shown the effect of MSC licensing 
with inflammatory cytokines on the immunomodulatory poten-
tial to the EVs (84, 96). Furthermore, considerations regarding 
the immunomodulatory potency of the vesicles in relation to 
their cellular counterparts need to be taken into account. A 
recent report on the immunosuppressive effect of BM-MSCs 
and their derived EVs has shown the latter were considerably 
less potent in suppressing T cell proliferation and preventing B 
cell differentiation (115). EVs were also seen to be not as effec-
tive in modulating DC maturation as their parent cells (101). In 
the future, it will be important to investigate the effect of MSC 
variability and licensing on the molecular signature of their 
derived vesicles. This notwithstanding, data indicate MSC-EVs 
are capable, at least in part, of mediating immunomodulatory 
responses; however, further research is needed to unravel their 
mode of action, the development of standardized EV purifica-
tion, characterization, and potency assays.
iMMUNOTHeRAPY wiTH ANTiviRAL 
T CeLLS TO TReAT iNFeCTiOUS 
COMPLiCATiONS
Opportunistic infections are serious complications affecting the 
morbidity and mortality of transplant patients (116). The most 
common infections in immunocompromised transplant recipi-
ents are caused by viral, bacterial, parasitic, and fungal pathogens 
(117). In immunocompetent individuals, the majority of these 
pathogens are controlled by the immune system, but in immu-
nocompromised patients they can lead to prolonged recovery or 
hospitalization due to recurrent reactivations and can even influ-
ence the overall survival (116). The most important risk factors 
for post-HSCT infections are immunodeficiency and mucosal 
injury caused by conditioning regimen pre-transplantation (118), 
allogeneic transplantation with T cell depletion (119), delayed 
immune reconstitution due to immunosuppressive therapy for 
GvHD, and the pathogen serostatus of donor/recipients pairs 
(120). Taking the risk factors into account, preventive and pre-
emptive treatments against these pathogens are important to 
promote engraftment, avoid relapse, and improve the overall 
survival. Bacterial, fungal, and parasitic infections can be treated 
with antibiotics, antifungals, or antiparasitic medications, but 
reconstitution of specific immunity is important. Latent virus 
reactivations or de novo infections can be treated with antiviral 
medications, but reactivation is only treated successfully or 
prevented by the recovery of anti-virus-specific T cells. The 
FiGURe 2 | Overview of the bioactive molecules secreted by MSCs and their impact on cells of the innate and adaptive immune response. Some 
bioactive molecules are constitutively expressed by MSCs, while others are “licensed” by exposure to an inflammatory environment or upon TLR stimulation (241). 
Depending upon the bioactive secretion profile, MSCs can skew the differentiation of CD4+ T-helper cells into various T-cell subsets, each with distinct cytokine and 
gene expression profiles, can promote the generation of regulatory T cells (Tregs) and inhibit the proliferation of cytotoxic T cells (242–244). MSCs can modulate the 
development of conventional and plasmacytoid DC (245–247) while DCs generated in the presence of MSCs have functional properties typical of tolerogenic DCs 
(248–250). Similarly, MSCs can polarize macrophages of the classical M1 pro-inflammatory phenotype to that of an alternative anti-inflammatory M2 phenotype 
(215), or directly induce this alternative phenotype by coculture (251). In contrast to other cell types, MSC modulation of B-cell function is poorly understood and the 
findings are contentious. Results from in vitro experiments show that while MSCs impair the proliferation and terminal differentiation of B cells (252) they have also 
been shown to stimulate antibody secretion (253). More recently, data have emerged which suggests that MSCs can promote the induction of regulatory B cells 
(Breg) (254). Neutrophils are an important mediator of the innate response and MSCs have been shown to enhance their survival through an IL-6-mediated 
mechanism, concomitant with the downregulation of reactive oxygen species, thereby conserving the pool of neutrophils primed to respond rapidly to infection 
(255). MSCs inhibit the proliferation and differentiation of monocytes to immature dendritic cells (DCs) (245). Natural Killer (NK) cells and MSCs have a reciprocal 
relationship; MSCs can inhibit the proliferation and cytotoxicity of resting NK cells and their cytokine production in vitro, while activated NK cells can be cytotoxic to 
MSCs (256). MSCs constitutively secrete Factor H which inhibits complement activation (257), conversely the complement activation products C3a and C5a 
released upon tissue damage are chemotactic factors for MSCs (258), recruiting them to sites of injury. Abbreviations: CCR, C-C chemokine; CD, cluster of 
differentiation; cDC, conventional dendritic cell; CTL, cytotoxic T-lymphocyte; GM-CSF, granulocyte-macrophage colony-stimulating factor; HGF, hepatocyte growth 
factor; HLA, human leukocyte antigen; IDO, indoleamine 2,3-dioxygenase; IFNγ, interferon-γ; Ig, immunoglobulin; IL, interleukin; MФ, macrophage; MHC, major 
histocompatibility complex; Mono, monocyte; Neutro, neutrophil; NF-κB, nuclear factor kappa B; PD-1, programed cell death protein-1; pDC, plasmacytoid 
dendritic cell; PGE2, prostaglandin E2; TGFβ, transforming growth factor β; Th, T-helper cell; TNFα, tumor necrosis factor α; tolDC, tolerogenic dendritic cell; TSG, 
TNF-α-stimulated protein.
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FiGURe 3 | Principle approach of adoptive T cell therapy for treatment 
of viral infections. Out of peripheral blood of the HSCT donor the 
virus-specific T cells are selected. The generated T cell product is infused into 
the patient suffering of viral complications after allogenic HSCT.
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prophylaxis and the treatment of transplanted patients with 
traditional drugs might be effective by killing the pathogens or 
control replication; however, virus infections or invasive fungal 
infections (121) are often refractory to these treatments due to 
limited activity, drug resistance, or short-term drug protection 
(122, 123). Furthermore, antiviral and antifungal drugs have 
demonstrated significant toxicity, which raises a real concern for 
HSCT patients undergoing intensive drug treatments (124, 125).
Cytomegalovirus (CMV) is a latent herpes virus, which may 
lead to mild diseases at first contact or remains silent during 
most of the life of immune competent individuals. CMV is 
latently expressed in 30–60% of the population (126). CMV 
persists life-long in infected individuals in endothelial and 
epithelial cells, but is usually controlled by T cells specific for 
CMV (127). Thus, in immunocompetent individuals, the infec-
tion with CMV is not problematic, in immunocompromised 
individuals, like HSCT patients, it can trigger severe diseases. 
The most common manifestations of CMV disease are gastro-
intestinal complications, pneumonia and interstitial pneumo-
nitis, hepatitis, retinitis, and encephalitis (128). Furthermore, 
several studies have reported a correlation between CMV infec-
tion and reactivation with the onset or aggravation of GvHD, 
which makes the treatment of these patients even more difficult 
considering that the immunosuppression required for GvHD 
will increase CMV reactivation (129).
Epstein–Barr virus (EBV) is a herpes virus spread in more 
than 90% of the adult population with a life-long latency in B 
lymphocytes (130). EBV de novo infection or reactivation affects 
about 11 and 46%, respectively, of patients undergoing HSCT 
(131). The most life-threatening condition related to EBV infec-
tion in immunocompromised patients is the posttransplant 
lymphoproliferative disease (PTLD) (132).
Adenovirus (AdV) is a common latent virus, which presents 
at least 51 serotypes having various clinical manifestations, which 
make the decision for a therapeutic strategy more complicated 
than for other viruses. The infection occurs frequently during 
the childhood, but the most susceptible individuals are pediatric 
patients after HSCT (120). In these patients, AdV infection can 
cause hepatitis, pneumonia, encephalitis, myocarditis, gastro-
enteritis, or nephritis and when disseminated is associated with 
more than 50% of mortality risk (120, 133).
Cytomegalovirus, EBV, and AdV are the major viral pathogens 
involved in infection complications after HSCT. Other critical 
non-viral infections occurring in HSCT patients are invasive 
fungal infections mainly caused by fungal pathogens, such as 
Aspergillus and Candida. The mortality among posttransplant 
patients with IFI is between 1 and 13% and occurs in the majority 
of the cases within the first year after HSCT (134).
Toward Adaptive T Cell Transfer 
for Treatment of viral infections
Viral reactivation is the result of impaired function of the 
immune system, thus adoptive transfer of virus-specific T cells 
can help to restore virus-specific immunity after HSCT. Over the 
last 20 years, adoptive T cell therapy has become a potential alter-
native to pharmacologic treatments for patients with refractory 
posttransplant infections (135–138). Donor lymphocyte transfu-
sion has been largely used in HSCT patients to prevent relapse 
by providing graft-versus-leukemia effect (GvL) although the 
development of GvHD has unfortunately been a concomitant risk 
(139, 140). In the early 1990s, it became evident that the practice 
of DLI was at the same time advantageous for the treatment of 
virus infections due to the presence of anti-virus reactive memory 
T cells among the lymphocytes from seropositive donors (141). 
Despite considerable benefits, the treatment of virus infections 
with DLI has demonstrated limitations concerning both safety 
and efficacy issues, due to the high presence of alloreactive T cells 
and to the low frequency of antigen-specific T cells (142, 143). 
These findings contributed to strategies increasing the number 
of antigen-specific T cells by selecting the donor target cytotoxic 
T  cells and depleting the alloreactive T cells as an alternative 
immunotherapy for the reconstitution of the anti-pathogen 
immunity with a reduced risk of triggering GvHD (Figure 3). One 
of the pioneering studies published by Riddell et al. demonstrated 
the successful reconstitution of antiviral-specific T cell immunity 
in HSCT patients at high risk of developing CMV disease by 
the prophylactic transfusion of in vitro expanded CMV-specific 
CD8+ T cell clones (143). Although they could show the reconsti-
tution of CMV-specific immunity, the expansion of virus-specific 
T cell clones had several drawbacks for integration into clinical 
practice. Since that time, innovative technological developments 
as well as novel basic immunological findings to improve and 
to disseminate the treatment of infectious diseases by adaptive 
anti-pathogen T cell transfer were developed.
In Vitro GMP Manufacturing of Antiviral 
T Cell Products
Basically two different strategies for depletion of potential 
alloreactive T cells and concomitant enrichment of relevant 
virus-specific T cells are established for the generation of GMP-
grade antiviral T cell products (Figure 4). One strategy relies on 
FiGURe 4 | Methods for in vitro generation of a virus-specific T cell 
product. For the in vitro manufacture process blood is used as the cellular 
source, mostly derived from the stem cell donor. Selection of virus-specific 
T cell and thereby depletion of potentially alloreactive T cells from the blood 
(Continued)
can be achieved by different methods. (A) Activation and expansion: 
peripheral blood cells are incubated with viral antigen. Antigen-presenting 
cells (APC) phagocytose, process, and present the antigen as peptides on 
MHC molecules. Virus-specific T cells recognize their cognate viral antigenic 
peptide via the TCR, get activated, and later on start proliferating for several 
days. In many applications, additional repetitive antigen restimulations are 
performed to further increase the expansion and thereby the number and 
the purity of the virus-specific T cell population. Dependent on the viral 
antigen and APC used for the process, either CD4+ and/or CD8+ T cells are 
contained in the product. (B) MHC class I/peptide multimer technology: 
virus-specific T cells within peripheral blood become labeled by a MHC 
class I/peptide multimer reagent, which binds to the TCR of the viral 
peptide-specific T cells. After an additional labeling step with magnetic 
beads the CD8+ virus-specific T cells are magnetically enriched. 
(C) Cytokine-capture assay: peripheral blood cells are incubated with viral 
antigen, e.g., a peptide pool, for 4 h. APC present the peptides on MHC 
molecules to virus-specific T cells, which start producing IFN-γ. Cells are 
labeled with a catch matrix consisting of a CD45 antibody conjugated to an 
Anti-IFN-γ antibody. In this way, secreted IFN-γ is specifically captured on 
the cell surface of the activated virus-specific T cells. Subsequently, the 
cell-bound IFN-γ is detected with Anti-IFN-γ magnetic particles and the 
virus-specific T cells are magnetically enriched. Both CD4+ and CD8+ T cells 
are obtained by this method.
FiGURe 4 | Continued
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conventional in vitro stimulation of blood cells with viral antigen 
and in  vitro propagated antigen-presenting cells (APC), like 
EBV-transformed B cells, and repetitive restimulation and long-
term culture to gain T cell clones or lines (143, 144) (Figure 4A). 
Despite successful optimization and simplification of multiple 
steps within this manufacturing over the last year to yield clini-
cally practical protocols resulting in effective and safe T cell lines, 
a main disadvantage of these cell products is the long and labori-
ous preparation time of at least 10 days (145). The development of 
new magnetic selection methods to obtain the rare virus-specific 
T cells out of peripheral blood, based on either IFN-γ secretion 
[CliniMACS® Cytokine Capture System (CCS) (IFN-gamma)] 
enables or peptide/MHC multimer labeling, allowed significant 
reduction of the preparation time of the cellular product under 
GMP conditions from one to two working days.
The peptide/MHC multimer technology allows selection of 
peptide-specific CD8+ T cells out of a blood sample according to 
the magnetic labeling of the antigen-specific T cell receptor (TCR), 
without the need of prior in vitro stimulation step (Figure 4B). 
The CliniMACS® CCS (IFN-gamma) requires stimulation of 
peripheral blood samples with antigen like peptides or proteins 
for about 4–16 h to induce IFN-γ production by the virus-specific 
T cells (Figure  4C). The secreted IFN-γ is specifically caught 
onto the cell surface of antigen-activated T cells using a capture 
matrix. The subsequent recognition of IFN-γ-secreting cells with 
magnetic beads conjugated to anti-IFN-γ antibodies enables its 
enrichment.
Both methods yield rapid and effective production of 
antigen-specific T cells. The advantage of the CCS over peptide/
MHC multimer technology is a parallel stimulation and selec-
tion of antigen-reactive CD4+ as well as CD8+ T cells. Although 
CD8+ cytotoxic T lymphocytes (CTLs) are responsible for the 
fast antiviral response, it has been shown that the presence and 
help of antigen-specific CD4+ T cells is essential to activate the 
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CTL and maintain long-term immunity (146). Moreover, the 
CCS enables generation of a cell product consisting of multiple 
viral epitopes of either one or more antigenic viral proteins. 
Whereas the number of available peptide/MHC multimer 
reagents is limited to the most common HLA/epitope spe-
cificities, the cytokine-capture assay is suitable for isolation of 
specific T cells independent of HLA allotypes. A disadvantage 
of the IFN-γ secretion assay technology compared to peptide/
MHC multimer technology is the need for a short-term (4 h) 
incubation phase for antigenic stimulation. However, exactly 
this technological feature makes it possible to generate tailored 
T cell products for patients by choosing on the required viral 
antigen, either peptides, pools of peptides, proteins, and even 
use of multiple antigens. Meanwhile a whole panel of viral 
protein antigens is available as pre-pooled GMP-grade peptide 
cocktails, covering CD4+ as well as CD8+ T cell epitopes without 
HLA restriction.
Despite the possibilities of adaptive virus-specific T cell 
therapy the number of clinical sites, which have GMP manu-
facturing unit and processes and thus offering such a treatment 
option to patients, is limited. One of the general obstacles of cell 
therapy is the complexity of the clinical manufacturing. Beside 
the demands on the infrastructure with clean rooms and various 
instruments, the generation of antigen-specific T cell products 
requires several different handling and intervention steps during 
the production process and skilled and well-trained operators 
are needed. To guarantee robust and reliable processes as well 
as safe and effective clinical products, a standardization of the 
cell manufacturing is essential, which can be accomplished 
by automation. A newly developed cell processing device, the 
CliniMACS Prodigy®, enables to run the complete CCS in an 
automated and closed system (60, 147). The cells are processed 
from the first until the last step within a closed and single-use 
tubing set. All process steps, i.e., cell preparation, cell stimula-
tion, labeling and washing steps, magnetic enrichment, and final 
formulation are performed automatically. Only a minimum of 
operator action is necessary to set-up sterile connections of all 
starting materials (blood sample, antigen, buffers, cell culture 
media, labeling, and separation reagents) to the tubing set, for 
programing the desired time of the process end, and for cell 
sampling to allow their quality control.
Quality of the Cellular Products 
Determines Clinical Outcome
Clinical Benefits Are Detected upon Transfer  
of Low Numbers of T Cells
The cell numbers obtained with either system for rapid mag-
netic ex vivo selection of virus-specific T cells is limited due 
to the low frequency of virus-specific T cells within peripheral 
blood. In vitro expansion of the specific T cells was considered 
to be essential for a successful adoptive therapy as in early 
clinical studies the number of transferred T cells were as high as 
several million cell/m2 body surface area (148, 149). However, 
various investigators treated patients with CMV-, EBV-, or 
AdV-specific T cells directly obtained after ex vivo isolation 
using the CCS and reported clinical efficacy (138, 150–153). 
Thus, this low number of transferred cells most probably are 
compensated by their high in vivo proliferating capacity in the 
lymphodepleted host, thus leading to sufficient antigen-specific 
T cell immunity and successful treatment of viral infections. 
It has been shown for tumor-infiltrating T cell products that 
longer periods of in vitro expansion reduce the clinical efficacy 
in vivo, hypothesized to be the result of enhanced terminal dif-
ferentiation of cells (154). The number of virus-specific T cells 
that can be isolated ex vivo using either method depends mainly 
on the frequency of specific T cells in donors’ peripheral blood. 
Usually the number of enriched T cells allows the transfer of 
less than 1 × 105/kg body weight of the patient, i.e., the number 
of transfused T cells is below the number of unselected T cells 
regarded as critical for GvHD induction (MUD/MRD: 1 × 106/
kg body weight). Thus, methods for rapid generation of cellular 
antiviral T cell products are of advantage compared to long-
term cell culturing processes.
Cotransfer of CD4+ T Cells Support In Vivo 
Effector Function of CD8+ T Cells
Controversial data on the protective role of CD4+ and CD8+ 
T  cells, the benefit of transferring both, antigen-specific 
CD4+ and CD8+ T cell subsets, or CD8+ T-cells alone still 
exist and need to be discussed. The prophylactic infusion of 
CMV-specific CD4+ T cells in patients without CMV-specific 
T helper response has been shown to increase the frequency 
of CMV-specific T cells in both CD4+ and CD8+ T cell sub-
populations and to eradicate the virus successfully (149). On the 
other hand, the transfusion of CMV-specific CD8+ T cells has 
been likewise efficient in clearing the viremia and increasing 
the frequency of donor CMV-specific CD8+ T cells as well as 
recruiting CD4+ T cells in the recipients (155). Riddell et  al. 
and Walter et  al. have transfused CMV-specific T cell clones 
and reported a progressive decrease of transferred CMV CD8+ 
T cell clones in patients who lacked CD4+ T cells (143, 148). 
Since then, several other studies have demonstrated the critical 
role of CD4+ T cells in both maintaining the functionality of 
cytotoxic CD8+ T cells (156, 157) and directly fighting the viral 
infection (158). Furthermore, in a multicentre study, Leen et al. 
observed that transfusion of either CD4+ or CD8+ T cells were 
equally protective against viral infections (159). The CD4+ T cell 
population remains, however, a controversial issue for adoptive 
immunotherapy, since several studies have reported a higher 
alloreactive potential of this T cell subset (160, 161).
Reduced Alloreactivity in In Vitro-Generated  
T Cell Products
The allogeneic reactivity of pathogen-specific T cells has been 
largely investigated and their potential to elicit GvHD needs 
still to be clarified, particularly with HLA-mismatched donors. 
Several in vitro studies have reported the cross-reactive poten-
tial of expanded virus-specific T cells toward allogeneic-HLA 
antigens (162–166). Single-viral antigen CD4+ and CD8+ T cell 
lines or clones, specific for CMV, EBV, VZV, and influenza virus, 
have shown in vitro to recognize and lyse allo-HLA class I and 
class II molecules also expressed on normal cell subsets (164). 
Long-time culture and the generation of clones under repeated 
immune stimulation may contribute to the in vitro alloreactivity 
FiGURe 5 | In vitro human skin explant assay as a model to investigate the potential of third-party CMv-specific T cells to elicit GvHR in an 
HLA-mismatched system. (A) CMV-specific T cells were isolated from blood of seropositive donors by IFN-γ secretion assay and expanded in vitro between 2 
and 4 weeks with IL-2 and irradiated feeder cells. (B) CMV-specific T cell lines and unselected PBMCs from the same donor where exposed to HLA-mismatched 
PBMCs (recipient’s cells) in a mixed lymphocyte reaction for 7 days followed by incubation with recipient’s skin for further 3 days. Then skin biopsies were collected, 
fixed in formalin, and stained with hematoxylin and eosin. (C) The histopathological damage in the skin biopsies displays a readout of the allogeneic-HLA reactions 
caused by T cell activation. The images show that CMV-specific T cells do not cause GvHR (Grade I) as opposed to Unselected PBMCs (Grade II and III) from the 
same donor.
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of T cell clones, reported. In the clinical setting, this alloreactiv-
ity has not been reported, not even in HLA-mismatched clinical 
conditions (163).
In vitro data clearly showed a high degree reduction of 
alloreactivity by selection and expansion of CMV- and AdV-
specific T cells using the CliniMACS® CCS (IFN-gamma) is 
achieved (167–169). One limitation of the data above is that 
the tests were not performed versus the recipients’ material. 
In practice, alloreactivity testing of the donor material versus 
the recipient material is not feasible due to the time it takes 
and the necessary collection of the relevant tissue since GvHD 
can affect the skin, the gut, and the liver. Moreover, there was 
no alloactivation reported in AdV-specific T cells stimulated 
with third-party HLA-matched unrelated donor cells in a 
mixed lymphocyte reaction (MLR) setting when compared 
with autologous stimulation, but a residual 28% of alloreactivity 
was shown in the HLA-mismatched MLR setting (150). Very 
recently, our team has demonstrated that CMV-CTL isolated 
by IFN-γ secretion assay and further in vitro expansion did not 
induce relevant cutaneous GvH tissue damage in the in vitro skin 
explant model while maintaining high level of antiviral activity 
(170). At low cell doses (5 × 105) none of CMV-CTLs led to GvH 
reactions in the HLA-mismatched recipient’s skin, whereas at 
the high cell dose (1 × 106) two of nine CMV-CTLs induced a 
mild GvH skin damage (Figure 5). Our observations contribute 
to further elucidate the knowledge on the immunogenicity of 
antiviral T cells supporting simultaneously their safety use in 
the clinical practice.
Furthermore, it is important to correlate the phenotype and 
functionality of the infused cells with the clinical outcome.
Clinical Trials Using Ex Vivo Magnetically 
enriched virus-Specific T Cells
Clinical trials to date have confirmed safety and efficacy of the 
adoptive transfer of virus-specific T cells. The Tables 5–7 sum-
marize the data of clinical studies performed with donor-derived 
CMV-, EBV-, and AdV-specific T cell products, either using 
T cell lines or directly ex vivo isolated T cells, administered for 
therapeutic or pre-emptive treatment after HSCT. We are going 
to discuss in more detail below the virus clearance and kinetics 
of virus-specific immune recovery after application of cellular 
therapies based on the two methods for ex vivo isolation of virus-
specific T cells, namely the IFN-γ secretion assay and the peptide/
MHC multimer selection technologies.
Clinical Trials Using CliniMACS® Cytokine 
Capture System (IFN-Gamma)
Several studies used the IFN-γ secretion assay to select antigen-
specific T cells (Tables  5–7). Feuchtinger and colleagues pub-
lished the clinical experience on 13 patients treated with the 
infusion of pp65-specific IFN-γ-secreting CD4+ and CD8+ cells 
for refractory CMV infections or CMV disease after HSCT (171). 
It was observed that in  vivo expansion of transferred cells was 
correlated with clearance or significant reduction of viremia. 
Furthermore, expansion was seen in CD4+ and CD8+ T cells and 
cells could be detected in vivo within an average of 3–6 weeks. 
TABLe 6 | Clinical trials with therapeutic treatment of eBv-specific T cells.
Reference Method No. pts Results Dose
Rooney et al. (144) In vitro stimulation and expansion of EBV-specific CD8+ T cells 10 Therapy: 3/3 responders 
Prophylaxis: 7/7 virus free
0.2–1.2 × 108 cells/m2
Haque et al. (269) In vitro stimulation and expansion of EBV-specific CD8+ and CD4+ 
T cells
8 4/8 Remission 106 cells/kg
Haque et al. (270) In vitro stimulation and expansion of EBV-specific CD8+ and CD4+ 
T cells
33 14/33 complete remission 
3/33 partial response
2 × 106 cells/kg
Heslop et al. (271) In vitro stimulation and expansion of EBV-specific CD8+ T cells 114 Therapy: 11/13 complete 
response 
Prophylaxis: All PTLD free
1–5 × 107 cells/m2
Doubrovina et al. (272) DLI or in vitro stimulation and expansion of EBV-specific CD8+ T cells 19 13/19 complete response 106 cells/kg
Gallot et al. (273) In vitro stimulation and expansion of EBV-specific CD8+ and CD4+ 
T cells
11 4/10 responders 5 × 106 cells/kg
Total In vitro stimulation and expansion 52/86 responders  
(w/o prophylaxis)
Moosman et al. (152) Direct isolation of EBV-specific CD8+ and CD4+ T cells using the CCS 6 3/6 responders 0.4–9.7 × 104 cells/kg
Icheva et al. (151) Direct isolation of EBV-specific CD8+ and CD4+ T cells using the CCS 10 7/10 responders 0.15–53.8 × 103 cells/kg
Total Direct isolation using the CCS 16 10/16 responders
Uhlin et al. (268) Direct isolation of EBV-specific CD8+ T cells using MHC-I-pentamers 1 1/1 complete response 1.8 × 104 cells/kg
Total Direct isolation using MHC-i-multimers 1 1/1 responder
TABLe 5 | Clinical trials with therapeutic treatment of CMv-specific T cells.
Reference Method No. pts Results Dose
Einsele et al. (149) In vitro stimulation and expansion of CMV-specific 
polyclonal CD4+ and CD8+ T cells
8 5/7 evaluable pts eliminated infection 107 cells/m2
Peggs et al. (262) In vitro stimulation and expansion of CMV-specific 
polyclonal CD4+ and CD8+ T cells
16 Pre-emptive therapy: 8/16 did not require 
antiviral treatment
0.2–1 × 105 T cells/kg
Bao et al. (263) In vitro stimulation and expansion of CMV-specific 
polyclonal CD4+ and CD8+ T cells
7 3/7 pts cleared infection 
1/7 pts reduced viral load
2.5–5 × 105 CMV-specific 
CD3+ cells/kg
Blyth et al. (264) In vitro stimulation and expansion of CMV-specific 
polyclonal CD4+ and CD8+ T cells
21 Pre-emptive therapy: 13/21 did not require 
antiviral treatment
2 × 107 CMV CTLs/m2
Koehne et al. (265) In vitro stimulation and expansion of CMV-specific 
polyclonal CD4+ and/or CD8+ T cells
16 14/16 pts eliminated infection 5 × 105–3 doses with 
1 × 106 T cells/kg
Total In vitro stimulation and expansion 68 23/30 responders (w/o pre-emptive therapy)
Feuchtinger et al. 
(171)
Direct isolation of CMV-specific CD8+ and CD4+ 
T cells using the CCS
18 15/18 responders 1.2–166 × 103 cells/kg
Peggs et al. (137) Direct isolation of CMV-specific CD8+ and CD4+ 
T cells using the CCS
11 Pre-emptive therapy: 2/11 did not require 
antiviral treatment
104 CD3+ T cells/kg
Meij et al. (266) Direct isolation of CMV-specific CD8+ and CD4+ 
T cells using the CCS
6 6/6 patients eliminated infection 0.9 × 104–3.1 × 105 cells/kg
Total Direct isolation using the CCS 35 21/24 responders (w/o pre-emptive therapy)
Cobbold et al. (267) Direct isolation of CMV-specific CD8+ T cells 
using MHC-I-tetramers
9 8/9 patients eliminated infection 1.2–33 × 103 cells/kg
Schmitt et al. (155) Direct isolation of CMV-specific CD8+ T cells 
using MHC-I-streptamers
2 Control of CMV-viremia in both patients 0.37 and 2.2 × 105 cells/kg
Uhlin et al. (268) Direct isolation of CMV-specific CD8+ T-cells 
using MHC-I-pentamers
5 4/5 responders 0.8–24.6 × 104 cells/kg
Total Direct isolation using MHC-i-multimers 16 14/16 responders
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The transferred pp65-specific T cell immunity could be detected 
for more than 6 months after infusion in single patients (171). 
Moosmann and colleagues used the IFN-γ capture assay and 
stimulation with peptides derived from EBV antigens to generate 
EBV-specific T cells to treat PTLD induced by EBV (152). Three 
out of six patients had complete and stable remission after fail-
ing treatment with rituximab, an anti-CD20 antibody together 
with low numbers of CD4+ and CD8+ EBV-specific T cells. 
TABLe 7 | Clinical trials with therapeutic treatment of Adv-specific T cells.
Reference Method No. pts Results Dose
Geyeregger et al. (274) In vitro stimulation and expansion of AdV-specific CD8+ and CD4+ T cells 2 1/2 complete response 104 CD3+ cells/kg
1/2 partial response
Total In vitro stimulation and expansion 2 2/2 responders
Feuchtinger et al. (150) Direct isolation of AdV-specific CD8+ and CD4+ T cells using the CCS 9 4/9 responders 1.2–50 × 103 cells/kg
Qasim et al. (153) Direct isolation of AdV-specific CD8+ and CD4+ T cells using the CCS 5 3/5 responders 
(cleared adenoviremia)
104 cells/kg
Feucht et al. (138) Direct isolation of AdV-specific CD8+ and CD4+ T cells using the CCS 30 21/30 responders 0.3–24 × 103 CD3+ 
cells/kg
Total Direct isolation using the CCS 44 28/44 responders
Uhlin et al. (268) Direct isolation of AdV-specific CD8+ T cells using MHC-I-pentamers 1 No response 3.1 × 104 and 
1.7 × 104 cells/kg
Total Direct isolation using MHC-i-multimers 1 0/1 responder
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Non-responders suffered from the late-stage disease with multio-
rgan dysfunction at the time of T cell transfer. In two responders, 
long-term follow up was possible, showing that EBV-specific 
T cells rapidly expanded upon transfer, high levels were main-
tained for approximately 6 months then the numbers declined, 
according to the characteristic expansion and contraction of 
antigen-specific T cells, and stabilized at levels characteristic 
for healthy individuals, providing protection for at least 2 years 
after transfer. Detailed analyses of cell differentiation markers 
early after transfer showed that EBV-specific CD8+ T cells had 
an effector memory phenotype (CCR7− CD45RA−), which after 
contraction evolved into central memory (CCR7+ CD45RA−) and 
terminally differentiated effector cells (CCR7− CD45RA+). It has 
also been shown that infusion of AdV-specific IFN-γ+ T cells was 
successful and their expansion in vivo correlated with decreased 
viral load (138, 150). The analysis of four AdV-specific T cell 
products before treatment revealed that the majority of cells were 
of effector memory phenotype, identified based on the expres-
sion profiles CCR7− CD45RA− and CD62L− CD45RO+, and a 
minority of central memory phenotype, characterized as CCR7+ 
CD45RA− and CD62L+ CD45RO+ (138). Further investigation 
on tracking of the infused cells and correlating the phenotype and 
functionality of the infused cells with the clinical outcome will in 
addition help to define the optimal conditions for a successful and 
long-lasting effect of the adoptive transfer.
Clinical Trials Using the Peptide/MHC  
Multimer-Based Selection
Nowadays, this technique is used for adoptive transfer, since it has 
been shown that antigen-specific CD8+ T-cells selected with pep-
tide/MHC multimers induced long-lasting immune responses 
without increasing the risk for GvHD (Tables 5–7). The devel-
opment of “reversible” TCR staining with streptamers allowed 
selection of the phenotypically and functionally unchanged cells 
(172, 173). Schmitt and colleagues reported results from the 
study on two patients treated with CMVpp65-specific T cells for 
recurrent CMV antigenaemia after HSCT (155). For one of the 
donors the phenotype and function of cells after transfusion was 
analyzed. Donor-derived CMV-specific T cells from the cellular 
product rapidly expanded in vivo, showed early after transfusion 
an effector memory phenotype (CCR7− CD45RA−), acquired 
effector phenotype (CCR7− CD45RA+) at later timepoints, and 
were capable of secreting IFN-γ upon in vitro stimulation. In both 
patients, clearance of the CMV reactivation without any signs of 
GvHD was observed. Additionally, Odendahl and colleagues 
showed in a pre-clinical study the potential of clinical-scale CMV 
streptamer-selected T cells. In this study, 22 cell products dis-
played excellent viability, cytotoxicty, and purity with effectively 
removed selection reagents (174). Recently, a GMP-compliant 
protocol using the streptamer technology was implemented to 
enrich EBV- and AdV-specific T cells. Because of the very low 
frequencies of EBV- and AdV-specific T cells in the starting mate-
rial, the purity (among CD3+ cells) of the large-scale cell product 
was poor, up to 44 and 6.7%, respectively. However, an increase 
in purity was achieved by small-scale selection or simultaneous 
application of EBV- and AdV-streptamers. An IFN-γ response 
was seen in most of the products and cells were predominantly 
of the effector memory (CD62L− CD45RA−) or central memory 
phenotype (CD62L+ CD45RA−), thus those cells are suitable for 
clinical use (175).
Future Perspectives
Generation of Multipathogen-Specific T Cells
Adoptive transfer of multi-antigen-specific T cells is a promising 
approach in restoring antigen-specific immunity and preventing 
or treating infectious complications after HSCT. Several strategies 
have been developed to simultaneously select T cells specific for 
viral and/or fungal pathogens. Initial studies focused on CMV, 
EBV, and AdV, using a clinical-grade AdV vector Ad5f35 with 
expression of the CMV antigen pp65 transgene, which permit-
ted transduction of APC like DCs or EBV-transformed B cells 
to successfully stimulate and expand virus-specific T cells (164, 
176–178). A new enrichment strategy based on the activation-
dependent CD154 (CD40L)-expression (transient expression on 
activated CD4+ and to lesser extent on activated CD8+ T cells) 
and subsequent expansion of T cell has been introduced to 
production of multi-pathogen-specific T cells without the need 
to genetically modify APC. This technique allowed generation of 
alloantigen-depleted CD4+ and CD8+ T cell lines within 14 days 
with high specificity for the most common posttransplantation 
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pathogens. These T cell lines showed extensive proliferative 
capacity and confirmed functionality in vitro (179). Recently, the 
use of either DNA plasmids or peptide pools to pulse APC has 
been validated to avoid safety and regulatory issues associated 
with transduction of APC using viral vectors. The combination 
of the peptide mixture approach or transfection of DC with 
plasmids with expansion in gas permeable rapid expansion 
(G-Rex) bioreactors provided further advances, increasing 
both feasibility and applicability of T cell therapy (180). These 
rapidly (10–12  days) expanded multi-virus-specific T cells 
provided effective antiviral protection in clinical trials (121, 
159). Certainly, the short-term activation concomitantly with 
peptide pools from multiple viral antigens in combination with 
the CliniMACS® CCS (IFN-gamma) provides the most simplest 
and fastest way for simultaneous GMP-grade selection of CMV-, 
EBV-, and AdV-specific CD4+ and CD8+ T cells.
Broadening the Clinical Use of Adoptive  
T Cell Therapy
Several barriers prevent the broader use of virus-specific T cell 
therapies after HSCT. One of the main hurdles is associated 
with the complexity of GMP-grade cell manufacturing. More 
details and suitable solutions are described for generation of 
virus-specific T cells in Section “In Vitro GMP Manufacturing 
of antiviral T Cell Products” and of gene-modified T cells 
in Section “Complexity of the Cell Manufacturing Process” 
of this article. A second main problem is connected with 
pathogen-naïve donors and umbilical cord blood transplants. 
For immunotherapy with cells derived from pathogen-naïve 
donors or cord blood, in  vitro priming of the donor T cells 
with APC pulsed with antigen or genetically modified APC 
can be introduced (177). Another option is the transfer of 
virus-specific TCR genes into donor primary T cells by viral 
vectors (181). The antigen-specific responses in recipient can 
be boosted also by the vaccination with peptide-loaded donor-
derived DC (182). Apart from above mentioned strategies, the 
selection of the virus-specific T cells from healthy seropositive 
third-party donors is an attractive alternative. Haque and col-
leagues showed for the first time that partially matched third-
party EBV-CTL led to the control of PTLD after solid organ 
transplantation (183). Also post-HSCT successful treatments of 
refractory viral infections (CMV, EBV, AdV) with third-party 
virus-specific T cells were reported (177, 184). A detailed sum-
mary on clinical results of third-party-derived virus-specific 
T cell administration is found in a recent review written by 
O’Reilly and colleagues (185). The first promising results using 
virus-specific T cells from third-party donors initiated the 
idea of donor registries and biobanks with the cryopreserved 
antigen-specific T cells, which could provide “off the shelf ” 
immunotherapy product (185).
The introduction of rapid manufacturing technologies such 
as magnetic enrichment processes for selection of pathogen-
specific T cells out of heterogeneous hematological populations 
offered new possibilities leading to successful application of 
adoptive T cell transfer in HSCT patients with refractory virus 
(CMV, EBV, ADV) infections (152, 171, 186) (Tables 5–7). More 
recently adoptive cell transfer has been developed for other 
virus infections, like Varicella Zoster virus, BK virus, or human 
herpesvirus 6 (121, 187) as well as for invasive fungal infections 
with aspergillus or candida (135).
iMMUNOTHeRAPY wiTH CAR  
GeNe-MODiFieD T CeLLS FOR 
TReATMeNT OF LeUKeMiAS
Despite the success of allogeneic HSCT in the quest for a cure 
of leukemic patients, the demand for alternative and new treat-
ment options is high, as relapse and refractory leukemia remain 
a major challenge for patients having with very poor prognosis 
(188–190). How to improve the antitumor immunity, especially 
in patients who are not eligible for HSCT, need of a bridge therapy 
prior to transplant, or even after failure of HSCT. In the future, 
will there be a way even to replace SCT and thereby avoiding 
transplantation-associated complications?
Elimination of the malignant cells and sustained remis-
sions can be achieved by induction of GvL effects after HSCT, 
which are based on a donor T cell-mediated immune response. 
Enhancement of the GvL effects is observed with DLI (191, 192). 
However, a treatment with the complete repertoire of allogeneic 
T cells is always accompanied by the substantial risk for the life-
threatening GvHD. One way to increase anti-leukemic effects 
while avoiding GvHD in allogenic transplantation settings is 
the transfusion of in vitro selected T cells, specifically targeting 
tumor-associated antigens. But the majority of described tumor-
associated antigens are not exclusively found in tumor cells, but 
represents self-antigens, either expressed in other adult healthy 
tissue or during embryonic development. In general, it is assumed 
the endogenous T cell repertoire against self-antigens show lim-
ited potency to eradicate tumor cells due to low affinity TCR. The 
most powerful T cells would target either neo-antigens derived 
from mutated genes within tumor cells or allogenic antigens like 
minor histocompatibility antigens with restricted expression in 
hematological cells, e.g., HA-1. These antigens are recognized as 
foreign proteins by the immune system (i.e., the T cell repertoire 
for these antigens is not shaped due to negative thymic selection 
of T cells expressing high-affinity TCRs). Another approach to 
break self-tolerance is the introduction of a new, high-affinity 
antigen specificity into the T cells, i.e., by genetic modification 
with an artificial TCR or with a CAR (12, 193).
Clinical Outcome of CD19  
CAR-Transduced T Cell Therapy
Recent success stories of therapy with CAR-modified T cells 
targeting CD19 in patients with high-risk B cell malignancies, 
such as chronic lymphocytic leukemia (CLL) or childhood acute 
lymphoblastic leukemia (ALL), have raised enormous scientific 
and public expectations. For example, in a clinical trial including 
30 children and adults with relapsed or refractory ALL treated 
with CD19 CAR–transduced T cells 90% of the patients achieved 
complete remission (194). The development of CAR T cell therapy 
and a summary of clinical studies and data generated within the 
past years have been described in several reviews and therefore 
will not further discussed in this article (195, 196).
FiGURe 6 | General workflow for adoptive therapy with CAR-modified 
T cells. Figure courtesy of Prof. Hinrich Abken.
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workflow of Adoptive Therapy with  
CAR-engineered T Cells
To prepare CAR-modified T cells for the treatment of a leukemic 
patient, first peripheral blood is drawn from the patient. The 
T cells are then isolated from the blood and engineered in vitro 
with a CAR targeting a pre-defined antigen on tumor cells. 
Subsequently, the cells are amplified to obtain a sufficient number 
of CAR T cells for transfusion into the patient (Figure 6). Before 
administration of CAR T cells, the patient undergoes a non-
myeloablative lymphodepletion, which supports the therapy, e.g., 
by promoting the in vivo proliferation and thus the persistence of 
CAR T cells.
engineering Potent and Safe  
CAR-Modified T Cells
Chimeric antigen receptors are artificially constructed recep-
tors introduced into somatic cells, mainly in T cells, by genetic 
engineering and redirect immune responses toward the tumor. 
A CAR consists of an extracellular antigen recognition motif, 
resembling a single-chain fragment of the variable region 
of an antibody (scFv), directed against a cell surface antigen 
expressed on a tumor cell (Figure  7). The scFv part is linked 
via a transmembrane domain to intracellular signaling struc-
tures derived from the TCR and costimulatory receptor(s). If 
CAR-engineered T  cells encounter tumor-associated antigens, 
the intracellular signaling cascades of the TCR/costimulatory 
moieties are triggered. Ultimately, this activation results in T 
cell effector function, i.e., cell proliferation, cytokine secretion, 
and cytolytic activity (197). Over the last years, the functional 
properties of CARs have been improved. First-generation CARs 
lacked the intracellular signaling motifs for costimulation. 
Effective T cell activation requires at least two types of signals: (i) 
engagement of the TCR with antigen presented by MHC and (ii) 
engagement of costimulatory molecules, such as CD28, OX40, 
and 4-1BB. However, tumors often do not express appropriate 
ligands for costimulatory molecules. To overcome these restric-
tions second-generation CARs were developed incorporating 
the intracellular domains of one costimulatory receptor, either 
CD28 or 4-1BB. T cells expressing such CARs had a higher 
capacity to expand, mediate increased tumor killing, and persist 
in vivo for a longer period of time compared to first-generation 
CARs (198–201). With the aim to further improve the func-
tionality of CAR-modified T cells, so-called “third-generation” 
CARs, which deliver more than one type of costimulatory signal, 
are now prepared for clinical trials.
Further efforts concentrate on strategies for design of T cells 
with the goal to overcome inhibitory T cell signaling, the sup-
pression by the tumor microenvironment, or tumor antigen loss, 
which is now regularly detected in a subset of patients suffering 
from relapses after CD19 CAR T cell therapy (202–208).
Other strategies for CAR T cell design aim toward increasing 
the safety of CAR T cells. One major concern of the therapy is the 
attack of normal tissues (“on-target, off-tumor” toxicity), which 
could dependent on the chosen target antigen result in very 
severe and life-threating toxicity (208). However, the elimination 
of normal B cells with, e.g., CD19 CAR T cells and the resulting B 
cell aplasia is regarded as an expected and acceptable “on-target, 
off-tumor” effect, which is successfully treated with infusion 
of gamma immunoglobulins. Another toxicity first observed 
with CD19 CAR T cells is the cytokine release syndrome (202, 
209, 210). It is a side-effect of the desired antitumor response 
induced by CAR T cells leading to mild, but in some cases to 
severe clinical syndromes, which requires intensive care and 
therapeutic management of the patients. Severe events are now 
effectively treated with blocking Anti-IL-6 receptor antibody 
without influencing the tumor rejection by the CAR T cells 
(211–213). Nevertheless, the need to prevent or substantially 
limit the toxicity of the therapy is high and potential solutions 
are under investigations (208, 214–216).
Advantages of CAR-engineered T Cells
Chimeric antigen receptors-modified T cells have some crucial 
advantages over natural T cells and in part also over TCR-
engineered T cells, as they can function independently of MHC 
molecules. First, the affinity of an antibody–antigen binding is in 
general much higher compared to a TCR–peptide/MHC binding. 
This provides at least the option to target antigens that are usually 
not detected by T cells, e.g., carbohydrates and glycolipids, which 
FiGURe 7 | Structure of different generations of CARs. Figure courtesy of Prof. Hinrich Abken.
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are frequently altered in tumor cells (217–219). Second, loading 
of antigenic peptide onto MHC requires antigen processing and 
presentation, and both processes are targets of tumor escape 
mechanisms resulting in the loss of antigen/MHC expression on 
malignant cells. Third, a CAR recognizes its antigen independent 
of individual MHC allotypes, resulting in the universal applica-
tion in all patients that express this antigen on the cell surface. In 
contrast a TCR is specific only for the combination of an antigenic 
peptide in the context with an MHC allele. Due to the MHC 
polymorphism in the human population, patient-specific or at 
least a panel of MHC allele/peptide-specific TCRs are needed 
to cover the human population comprehensively. Last, not only 
CD8+ T cells, but also CD4+ T cells can be engineered, which 
allows for T cell help independent of MHC class II expression. 
A clear disadvantage of CARs is that only cell surface antigens can 
be targeted, while intracellular tumor antigens remain invisible. 
However, the recognition of MHC/peptide complexes by CARs is 
not excluded (220), which might also facilitates access to intracel-
lular tumor antigens.
As learned from the outcome of the clinical application of ex 
vivo expanded melanoma-infiltrating T cells over the last years, 
the key factors for a successful adoptive T cell therapy to target 
cancers are the selection of the best possible tumor antigen, the 
in vivo persistence of transferred T cells and their accessibility to 
the tumor. Beyond that, a reliable and reproducible manufactur-
ing procedure leading to high-quality cellular products is a crucial 
element of the therapy (193). We will focus our discussion in the 
next sections on the demands and challenges connected to the 
manufacturing process and will disclose recent progress toward 
the implementation of therapy with CAR-engineered T cells into 
clinical practice.
Complexity of the Cell Manufacturing 
Process
Currently, therapies with CAR-modified T cells are mainly applied 
in the context of clinical trails by investigators, according to their 
own manufacturing process utilizing existing infrastructure with 
clean rooms, instruments etc. The in vitro preparation of CAR 
T cells is a quite complex process and lasts for several days to 
weeks. So far, most concepts for CAR T cell therapies are based 
on autologous cells, which means that each cellular product is 
manufactured in a single batch in small scale for a single patient. 
It starts with isolation of peripheral blood cells, e.g., by an initial 
leukapheresis step. Blood is drawn either from the patient directly 
(autologous therapy) or – in the case of a patient who received 
stem cell transplantation – from the stem cell donor (allogeneic 
therapy). Then T cells are enriched from the blood, activated, 
and subsequently gene-modified with viral or non-viral vectors 
encoding the CAR. The CAR-modified T cells are amplified to 
obtain larger numbers of cells and finally formulated and/or cryo-
preserved prior to infusion into the patient. Several in-process 
and quality control analyses of the cell product are required to 
guarantee the safety and quality of the final cellular end product 
(Figure 8). This multi-step workflow poses high demands on the 
infrastructure, is labor intensive, and requires various different 
techniques, devices, reagents, handling steps, and skilled and 
extensively trained operators. Within a small-scale clinical trial 
the entire process can be executed in a semi-automated manner 
with the use of several devices for single process steps according 
to GMP guidelines. To date only a restricted number of GMP 
facilities worldwide are able to carry out this manufacturing 
process. But in the light of the encouraging clinical outcomes, 
the need for a broadly applicable therapy is high. However, the 
transformation of such a manufacturing process into a routine 
and large-scale setting has some pitfalls. An optimization and an 
upscaling of the manufacturing process is one of the key factors 
for the dissemination of this therapy.
Manufacture of High-Quality Cell Products 
Requires Robust and Reproducible Cell 
Processing
A favorable outcome of cell therapy depends on a robust and 
reproducible manufacturing processes resulting in safe and 
clinically effective cell products. Currently, many investigators 
FiGURe 8 | In vitro manufacture process of a CAR-engineered T cell product.
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and companies are developing solutions, including instruments, 
reagents, and consumables, for GMP-grade cell manufacture 
(221). Robustness of the cell manufacturing process, which will 
eliminate failure risks and allow standardization, can be improved 
by several means.
(1) Operation in a “closed” system in contrast to “open” pro-
cessing minimizes the risk of contamination and therefore 
failure of production. Maintaining the sterility of the cell 
product is essential. All interventions during cell process-
ing, like addition or exchange of reagents and buffer/media 
during washing, feeding, activation, transduction, and sam-
pling steps bear the risk for product contamination. Closed 
systems are set-up with equipment that allows processing of 
cell without its exposure to the room environment, but keep-
ing sterile conditions. Suitable closed systems are, e.g., bags 
with closed tubing pathways and connections. Introduction 
of material into closed systems is possible, e.g., via sterile 
filters. A suitable simplified and semi-closed cell culture 
system for CD19 CAR T cell production has been described 
(222). Closed systems might enable operators to work under 
less advanced GMP clean room conditions, which is more 
cost effective and easier to establish.
(2) The use of enriched T cells as starting material for the 
activation process helps to achieve higher reproducibility 
in the manufacturing process. Patient’s blood samples are 
highly variable in their cellular composition and one of the 
most critical parameter for reproducible cell processing. 
Instead of using the entire blood cell fraction for gene 
modification, isolation of T cells or even T cell subsets 
prior to modification is favorable for various reasons. Most 
patients are heavily pre-treated, which often give rise to 
abnormal or immunosuppressive blood cell populations or 
even low-responding T  cells (223–225). Moreover, it has 
been shown that activation and expansion of the T  cells 
is substantially enhanced when T cells were isolated from 
the blood product to eliminate suppressive influences 
(222, 226, 227). Currently, particular T cell subpopulations 
are under investigation with the aim to improve in  vivo 
persistence and effector function of adoptively transferred 
CAR-modified T cells. One strategy is based on the modi-
fication of patient’s endogenous CMV- or EBV-specific 
T cell pools, which contain long-living memory cells 
(228). In  addition, persistence of these CAR-modified 
T cells might be promoted by triggering the natural TCR 
in vivo upon reactivation of those latent viruses. A further 
advantage of CAR-modified virus-specific T cells is that 
they provide protection in the case of viral reactivation 
after lymphodepletion (228–230). A disadvantage of this 
concept is the need to implement the generation of virus-
specific T cells into the manufacturing process, which adds 
more complexity to the whole process, is time consuming, 
and might affect functionality of the cells, especially if long-
term culturing is required to obtain virus-specific T  cell 
populations. Alternatively, the naive, central memory, or 
stem memory T cell subset, which have been described to 
have essential functional advantages, are regarded as an 
appropriate starting population (231–235).
 A straightforward and closed system for GMP-grade 
and large-scale T cell processing is the combination of 
Dynabeads® CD3/CD28 CTS™, a large magnet (both 
offered by Thermo Fisher Scientific), and bags to enrich and 
concomitantly activate T cells from whole blood products 
(236). A versatile, reliable platform for closed, clinical-scale 
magnetic enrichment of either all T cell types or naive and 
central memory T cell subsets is the CliniMACS® System, 
encompassing separation reagents and the CliniMACS 
Plus Instrument developed by Miltenyi Biotec, Bergisch 
Gladbach, Germany (237, 238). For T  cell activation a 
reagent (MACS® GMP TransAct™ CD3/CD28 Reagent) 
consisting of a biodegradable polymeric nanomatrix coated 
with agonists for CD3 and CD28 is available, which allows 
for efficient viral transduction (237). This reagent is in 
compliance with relevant GMP guidelines. It can be sterile 
filtered, which makes it a highly valuable tool for aseptic cell 
manufacturing.
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(3) Simplification of the cell processing by automation improves 
reproducibility and reduces resources for operators and 
thus increases productivity. The CAR T cell manufacturing 
involves various process steps, like cell enrichment, cell 
culturing, final formulation of the product and in between 
cell washing, concentration, feeding, and rebuffering. In 
addition, in-process and quality controls samplings are per-
formed. Several commercially available devices allow the 
run of single or few steps of the process (221). Nevertheless, 
multiple instruments and systems need to be implemented 
for execution of the whole process, which challenge the 
manufacturer in many ways. The different devices and the 
procedures need to be adjusted to each other to achieve a 
feasible and safe process. Substantial manual handling steps 
and user interactions are required. Additionally, each device 
demands installations, services, qualifications, and training 
of operators. A new device, the CliniMACS Prodigy® instru-
ment (Miltenyi Biotec), is designed as an all-in-one solution 
for automated cell processing in a closed GMP-compliant 
system (60). A process specifically developed and optimized 
for the manufacture of CAR T cells on this instrument is 
now available. With this process, the entire workflow for 
the manufacture of CAR T cells, starting with T cell enrich-
ment through to final formulation, can be performed in a 
single-use tubing set with minimal operator interaction. 
The complex CAR T cell production process includes many 
different reagents, i.e., T cell separation reagents, activation 
and expansion reagents, viral vectors, cell culture media, 
cytokines, and buffers. Importantly, for the use of the 
CliniMACS Prodigy® all these reagents are developed to 
efficiently and stably work together as an integrated reagent 
system. This CliniMACS Prodigy® approach significantly 
simplifies the manufacturing process. In addition, due 
to the integrated solution it allows easy implementation 
in GMP facilities and can boost CAR T cell therapy to a 
standard-of-care.
Future Perspectives: Commercialized 
Manufacture of Personalized engineered 
Cellular Products
Today, most CAR T cell products are manufactured for phase 
I/II trials in a limited number either within clinical centers or 
facilities of commercial providers. At least with entering into 
phase II/III clinical trials new considerations have to be taken 
into account as the number of patients to be treated increases to 
hundreds or thousands per year. Production, infrastructure, and 
logistics for shipment of cellular materials have to be set up to 
guarantee the manufacturing of these high quantities in a high-
quality and cost-effective manner and with compliance of all the 
regulatory requirements. To achieve these goals the process needs 
standardization and scale-up. In the end, a therapy must fulfill 
economical requirements to be available as a standard-of-care for 
patients.
Chimeric antigen receptors T cell therapy applied in the 
moment is cost-intensive as individualized products have 
to be generated starting with patient-derived cells. Several 
investigators are currently evaluating options to reduce the 
costs of cell production by depersonalizing T cell therapy, e.g., 
using off-the-shelf third-party T cells modified for knock-out 
of the endogenous HLA class I, TCR and/or CD52 expres-
sion for subsequent gene engineering with artificial antigen 
 receptors (239, 240).
In principal, two different models for clinical cell manufac-
turing are discussed (221). A production line, as established 
for automated industries, where the manufacturing process 
for one patient product is structured in sequential operations, 
which are performed with specialized and dedicated personnel 
in physically separated spaces of the facility. In line with this 
concept is, e.g., the Xvivo modular laminar flow system from 
BioSpherix (Lacona, NY, USA), which enables the transport 
of cells through a whole series of areas. Due to the high 
investment for establishing a production line including the 
efforts required for organization of the infrastructure for cell 
shipments, a centralized manufacturing in highly specialized 
large facilities rather than a decentralized, local production at 
patients’ point-of-care is of favorite. The second model relies 
on devices such as the CliniMACS Prodigy®, to handle one 
cell sample in one instrument at a time in an automated way 
and with only a minimum of user interactions. Within one 
facility numerous devices can be run in parallel and completely 
independently from each other. The device-based system is in 
accordance with a centralized as well as a decentralized organ-
ized cell manufacturing and therefore an attractive solution 
for commercial providers having large or smaller facilities, 
including hospital located sites.
CONCLUSiON
Within the last years, the cellular immunotherapy field, especially 
in the context of hematological malignancies, gained tremendous 
attention by scientific researchers, clinicians, as well as commer-
cial entities, thanks to the substantial progress made in multiple. 
The better scientific understanding of immunological mechanism 
and the novel advanced ideas and technologies for cell engineer-
ing and manufacturing have enabled the design of improved 
clinical approaches, which are currently being evaluated within 
clinical trials. The next step has to be the translation and broad 
implementation of these treatments into clinical routine. This 
requires on the one hand the selection of the best therapeutic 
options with maximal clinical benefit for the patients and on the 
other hand that the economical needs are met for all: the pharma-
ceutical companies and clinical entities involved in bringing the 
therapy to the patient, and the payers, who reimburse the therapy, 
i.e., health insurances.
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